About This Trial
A multicenter, prospective, observational registry of CLL patients who are initiating approved oral kinase inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures.
- Status: Enrolling now
- Location: Atrium Medical Center
- Study type: Observational
- Ages eligible for study: 18 years and older
- Genders eligible for study: Both
- Principal Investigator: Dr. Nikki Okoye
- For more information about this study, visit ClinicalTrials.gov: NCT02582879
Contact Us
If you would like information about participating in this study, contact:
Sandy Fletcher, BSN, RN, CNOR, OCN, CCRP
(513) 420-5674
slfletcher@premierhealth.com